

Page 90 (Abstract), after the last line, beginning on a new page, please insert the attached substitute Sequence Listing.

REMARKS

Claims 10-22 are active and under consideration in this case.

Applicant submits that the sequence information recorded in the computer-readable Sequence Listing filed September 29, 1999, in the parent application (U.S. Serial No. 08/703,106), is identical to the paper copy of the Sequence Listing attached herewith.

Accordingly, it is believed that the present application is now in condition for examination in the merits.

Favorable consideration is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

William E. Beaumont
Registration No. 30996



22850

Telephone: (703) 413-3000
Facsimile: (703) 413-2220

ATTORNEY DOCKET NO.: 201803US0DIV
SERIAL NO.: 09/761,667

MARKED-UP COPY

Serial No.: 09/761,667
Amendment Filed On: Herewith

IN THE SPECIFICATION

Pages 29-30, replace the paragraph beginning at line 21, page 29 to page 30 with the following paragraph:

--In Infection and Immunity, Vol. 60, p.1568-1576, 1992, it is reported that it is possible that 9 amino acids are further bonded to the C-terminus of 434 [amion] amino acids in 47K. Therefore, as shown in FIG. 2, at the amplification of the DNA fragment of 47K, a DNA fragment which encodes 47K was prepared by adding a DNA sequence corresponding to the 9 amino acids to the antisense primer to be used (SEQ ID NO: 30).--

Page 90 (Abstract), after the last line, beginning on a new page, please insert the following substitute Sequence Listing.